Solardis Health Ventures

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

CardiaCare is a developer of a wearable medical device aimed at the non-invasive treatment and monitoring of atrial fibrillation (AFib) in patients. The company's innovative device employs a closed-loop approach combined with machine learning algorithms to deliver personalized peripheral neuromodulation. This technology mediates a cardiovascular antiarrhythmic response, enabling users to effectively reduce the burden of atrial fibrillation and its precursors, such as premature atrial contractions. As a result, CardiaCare’s solution offers users rapid clinical and symptomatic relief, providing a valuable tool for managing their condition in a home setting.